Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nemtabrutinib versus investigator's choice of ibrutinib or acalabrutinib as first-line treatment for CLL/SLL
CTR20241240Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nemtabrutinib, ibrutinib, acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Merck & Co.. Started Jun 2024; status: active.
02
Drugs
nemtabrutinibibrutinibacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20241240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241240.